Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers.
Li Y, Jiang T, Zhou W, Li J, Li X, Wang Q, Jin X, Yin J, Chen L, Zhang Y, Xu J, Li X. · 2020
Read Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. by Li Y, Jiang T, Zhou W, Li J, Li X, Wang Q, Jin X, Yin J, Chen L, Zhang Y, Xu J, Li X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7035327.txt.
Introduction
Li and co-authors chart immune-related long noncoding RNAs across cancers in Nature Communications. Long noncoding RNAs help control gene expression and play basic roles in immune regulation. The team built an algorithm called ImmLnc that finds which of these RNAs regulate immune pathways, then charted that regulation across 33 cancer types.
Cancers from similar tissues tended to share the same RNA regulators. The immune-related RNAs often showed disturbed expression in tumours and tracked closely with immune cell infiltration, which makes them candidate biomarkers. ImmLnc also split non-small cell lung cancer into three subtypes: proliferative, intermediate, and immunological. Those subtypes differ in mutation burden, immune makeup, chemotherapy response, and prognosis. The pipeline and data form a resource for hunting new immunotherapy targets.
Catalog record
| CREATOR | Li Y, Jiang T, Zhou W, Li J, Li X, Wang Q, Jin X, Yin J, Chen L, Zhang Y, Xu J, Li X. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers By Yongsheng Li, Tiantongfei Jiang, Weiwei Zhou, Junyi Li, Xinhui Li, Qi Wang, Xiaoyan Jin, Jiaqi Yin, Liuxin Chen, Yunpeng Zhang, Juan Xu, Xia Li Published in: Nature Communications DOI: 10.1038/s41467-020-14802-2 ABSTRACT Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression and they play fundamental roles in immune regulation. Here we introduce an integrated algorithm, ImmLnc, for identifying lncRNA regulators of immune-related pathways. We comprehensively chart the landscape of lncRNA regulation in the immunome across 33 cancer types and show that cancers with similar tissue origin are likely to share lncRNA immune regulators. Moreover, the immune-related lncRNAs are likely to show expression perturbation in cancer and are significantly correlated with immune cell infiltration. ImmLnc can help prioritize cancer-related lncRNAs and further identify three molecular subtypes (proliferative, intermediate, and immunological) of non-small cell lung cancer. These subtypes are characterized by differences in mutation burden, immune cell infiltration, expression of immunomodulatory genes, response to chemotherapy, and prognosis. In summary, the ImmLnc pipeline and the resulting data serve as a valuable resource for understanding lncRNA function and to advance identification of immunotherapy targets. INTRODUCTION Misregulation of gene expression programs has been found to cause a broad range of human diseases1. Gene expression in humans is controlled by thousands of regulators, such as transcription factors, chromatin regulators, and noncoding RNAs (ncRNAs)2. Cancer transcriptome analysis has identified thousands of lncRNAs that are associated with different types of cancer3. However, knowledge about their function in cancer is still limited. Much research has been focused on the function of lncRNAs and their mechanisms of action are even more diverse. Early studies primarily demonstrated that lncRNAs are related to diverse cellular responses, such as cell proliferation, apoptosis, and differentiation4–6. In addition, increasing studies have reported that the tumor microenvironment plays important roles in cancer development and progression. Dysregulation of the immune system can be a major cause of the development of cancer and immunotherapy has emerged as a promising cancer treatment strategy7. Thus, precise regulation of the expression of immune genes is critical for generating a robust immunity. However, the majority of studies so far have focused on coding genes, particularly the function of cell-surface receptors, cytokines, and transcription factors. Recently, increasing evidence has revealed that lncRNAs can play fundamental roles in the regulation of the immune system8,9. For example, the lncRNA NeST has been found to be related with T-cell activation and to be critical for immune response regulation10. The lncRNA NRON has been demonstrated to maintain a resting state of T cells by sequestering phosphorylated NFAT in the cytoplasm11. The oncogenic lncRNA LINK-A downregulates cancer cell antigen presentation and intrinsic tumor suppression12. However, only a few immune-related lncRNAs have been found to play a role in cancer so far12–14. Therefore, further studies on lncRNAs and their roles in immune regulation will be essential to identify immunotherapy targets in cancer. To systematically identify immune-related lncRNAs that are involved in cancer, we integrated multi-omics data of 33 cancer types and proposed the ImmLnc pipeline. We identified several lncRNAs that are related to immune pathways, which we further validated by independent datasets. We found that these immune lncRNAs are likely to be highly expressed in immune cell populations, show expression perturbation in cancer, and are significantly correlated with immune cell infiltration. With the examples of cancer-related lncRNA prioritization and cancer subtyping, we demonstrate that ImmLnc is a valuable resource for investigating the function of lncRNAs in cancer. RESULTS Identification of immune-related lncRNAs across cancer types To identify candidate lncRNA regulators that are correlated with immune-related pathways, we proposed a three-step computational framework called ImmLnc (Fig. 1a). ImmLnc systematically infers candidate lncRNA modulators of immune-related pathway activity from a large collection of sample-matched gene and lncRNA expression profiles. We reasoned that if the lncRNAs play important roles in immunology, then their correlated genes should be enriched in the immune-related pathways. Briefly, ImmLnc identifies the lncRNA modulators in three steps (Fig. 1a). First, genome-wide gene and lncRNA expression profiles of the same tumor patients were collected. Second, we calculated the tumor purity for each patient and genes were ranked based on the RS score for each candidate lncRNA. Third, we computed for each lncRNA its activity in immune pathways (lncRES) based on the modified gene set enrichment analysis (GSEA)15,16. The P-value of GSEA was converted to a lncRES score and the lncRNA–pathway pairs with lncRES > 0.995 and a false discovery rate (FDR) < 0.05 were selected.Fig. 1Identification of immune-related lncRNAs across cancer types.a Schematic illustration of three steps of ImmLnc for the identification of lncRNA regulators. b The number of patients in each cancer type. Cancers with similar tissue origin are grouped together. c The number of genes in 17 immune-related pathways. d The number of immune-related lncRNAs identified in each cancer type. The top y-axis shows the number of lncRNAs and the bottom y-axis shows the proportion of lncRNAs. Source data are provided as a Source Data file. Taking advantage of the multi-omics data in The Cancer Genome Atlas (TCGA), we employed ImmLnc for the genome-wide identification of lncRNA modulators in >11,000 samples across 33 cancer types (Fig. 1b and Supplementary Data 1). In particular, we focused on 17 immunologically relevant gene sets representing distinct immune pathways derived from ImmPort17, which is one of the largest open repositories of immunological data. Three to 516 genes were involved in these pathways (Fig. 1c and Supplementary Data 2). When ImmLnc was applied to 33 cancer types, the genome-wide screening yielded a collection of lncRNA pathways. On average, each cancer type yielded ~2000 lncRNAs that were correlated with immune pathways (Fig. 1d). Higher number of immune-related lncRNAs were identified in the cancer types in which more lncRNAs are expressed (Supplementary Fig. 1). These immune-related lncRNAs accounted for ~25% of all lncRNAs. Higher number of lncRNAs were correlated with the “Cytokines” and “Cytokine Receptors” pathways across cancer types (Supplementary Fig. 2). The cytokine and chemokine system represents an emerging potential target for immunotherapy18, and these lncRNA modulators will be a resource for dissecting the immune regulation underlying cancer. Moreover, we applied the ImmLnc pipeline to two datasets across immune cell populations (details are described in the Methods section). We found that the lncRNA–pathway pairs significantly overlapped with those identified in tissue datasets (Supplementary Data 3). All these results suggest that ImmLnc is able to identify the critical lncRNAs involved in immunology and constitutes a valuable resource in the development of precision medicine. Expression perturbation of lncRNA regulators in cancer To gain insight into the function of immune-related lncRNAs, we further examined the 500 top-ranked lncRNA–pathway pairs that are identified in multiple cancer types (Fig. 2a and Supplementary Data 4) and identified a lncRNA–pathway regulatory network. This regulatory network involves 241 lncRNAs and 13 immune pathways. The majority of these lncRNAs were correlated with “Cytokines” (Supplementary Fig. 3a). In addition, we investigated the expression of these lncRNAs and found that a large number of lncRNAs are upregulated in cancer (Fig. 2a). For example, MIAT, which has been demonstrated to be an oncogenic lncRNA by promoting the cell growth and metastasis19, shows more than threefold upregulation in ten cancer types (Supplementary Fig. 3b).